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Bisphosphonates are the gold standard for preventing skeletal-related events in patients with bone-
metastatic cancer and have been investigated for reducing cancer treatment-induced bone loss. Evidence
suggests bisphosphonates also offer anticancer beneﬁts in adjuvant and advanced cancer settings. We
conducted a retrospective analysis of data from a single-center, unselected cohort of women with early
breast cancer (N¼1646: 962 received adjuvant bisphosphonates, 684 did not) to assess the impact of
bisphosphonates on disease-free and overall survival. The bisphosphonate group comprised all women who
started bisphosphonate treatment within 1 year of breast cancer diagnosis and received Z3 months of
bisphosphonate treatment (zoledronic acid, clodronate, ibandronate, or alendronate; majority received
zoledronic acid). Disease-free survival was deﬁned as the time from breast cancer diagnosis until ﬁrst
disease recurrence or death. Treatment groups were balanced for cancer stage, hormone receptor
expression, and human epidermal growth factor receptor-2 expression. Patients in the no-
bisphosphonate group were more likely to be Z75 years of age, node-negative, and have histologic grade
3 tumors. In patients treated with adjuvant bisphosphonates, disease-free survival was signiﬁcantly longer
than in those who did not receive bisphosphonates (P¼0.0017). Both disease-free and overall survival were
signiﬁcantly longer in patients with hormone receptor-positive disease irrespective of lymph node status
(disease-free survival: P¼0.0038; overall survival: Po0.0026). No signiﬁcant disease-free survival
difference was detected in patients with hormone receptor-negative disease. This large, retrospective
study demonstrates a signiﬁcant survival beneﬁt with adjuvant bisphosphonates in patients with early
breast cancer, particularly in patients with node-positive and hormone receptor-positive disease.
& 2013 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Third-generation aromatase inhibitors (letrozole, anastrozole,
and exemestane) have now largely replaced tamoxifen as the
standard of care for postmenopausal women with hormone
receptor-positive breast cancer because of their greater efﬁcacy
[1,2]. Aromatase inhibitors block the production of peripheral
estradiol precursors and reduce endogenous estrogen to levels
substantially below those naturally occurring in healthy postme-
nopausal women [3]. Because estrogen is a negative regulator of. This is an open access article un
fax: þ49 6421 28 67070.
Hadji),
iebers.de (J.W. Siebers).bone turnover, its depletion during aromatase inhibitor therapy
results in increased bone turnover and osteoclast activity, and
leads to rapid reduction in bone mineral density and increased
risk of fractures [4,5]. Bisphosphonates (BPs)4 inhibit osteoclast-
mediated bone resorption, and thus can reduce or prevent bone
loss during aromatase inhibitor therapy. Intravenous (IV) and oral
(PO) BPs such as zoledronic acid, pamidronate, clodronate, and
ibandronate are approved for reducing the risk of skeletal-related
events (SREs) in patients with metastatic bone disease, and have
demonstrated efﬁcacy for preventing cancer treatment-inducedder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
4 ABCSG-12, Austrian Breast and Colorectal Cancer Study Group-12; AZURE,
Adjuvant Zoledronic acid to redUce REcurrence; BP, bisphosphonate; CI, con-
ﬁdence interval; DFS, disease-free survival; ERþ , estrogen receptor-positive; HR,
hazard ratio; IV, intravenous; OS, overall survival; PgRþ , progesterone receptor-
positive; PO, oral administration; RANKL, receptor activator of nuclear factor
kappaB ligand; SRE, skeletal-related events; TNM, tumor-node-metastasis; ZO-
FAST, Zometa–Femara Adjuvant Synergy Trial.
Table 1
Patient demographics and baseline disease characteristics.
BP group
(N¼937)
No-BP group
(N¼630)
P value
Age, years
Mean (SD) 59.5 (12.8) 64.9 (13.4) o0.001
o40 45 5% 23 4% 0.032
Z40 892 95% 607 96%
o75 819 87% 464 74%
Z75 118 13% 166 26% o0.001
BMI, median (SD) 26.9 (5.0) 27.3 (5.4) 0.28
Cancer stage
T1 620 66% 401 64% 0.88
T2, T3, or T4 317 34% 229 36%
Nodal status
N0 537 57% 413 66%
Nþ 400 43% 217 34% 0.0003
Histologic grade
G1 or G2 662 71% 421 67%
G3 275 29% 209 33% 0.19
ER-positivea
Z10% of cells 778 83% 509 81% 0.36
o10% of cells 159 17% 121 19%
PgR-positivea
Z10% of cells 660 70% 453 72% 0.40
o10% of cells 277 30% 177 28%
HER2 status
HER2 positive 125 13% 75 12% 0.29
HER2 negative 750 80% 517 82% 0.29
Adjuvant therapy
P. Hadji et al. / Journal of Bone Oncology 2 (2013) 2–10 3bone loss in patients with breast cancer [5]. Denosumab, a mono-
clonal antibody against the receptor activator of nuclear factor
kappaB ligand (RANKL), has emerged as an alternative to BPs for
reducing the risk of SREs in patients with bone metastases from
solid tumors, including breast cancer [6,7]. However, the long-term
side-effect proﬁle of denosumab is still unknown, and no guidance
currently exists for managing the risk of hypocalcemia. Because
denosumab has a short history of clinical use and has not demon-
strated anticancer activity, it was not included in this study.
A growing body of evidence supports the anticancer beneﬁts of
BPs above and beyond their bone-conserving effects. In recent
retrospective (N¼154,768) and population-based (N¼9950) stu-
dies in healthy women, BP treatment was associated with
reduced risk of breast cancer [8–10]. Preclinical and clinical data
suggest that BPs may provide anticancer beneﬁts such as inducing
cancer cell apoptosis; inhibiting cancer cell proliferation, migra-
tion, invasiveness, and tumor-associated angiogenesis; activating
anticancer immune activity; and potential synergy with antic-
ancer agents [5,11–13]. Several pilot clinical studies in women
with early breast cancer demonstrated that adding (neo)adjuvant
zoledronic acid (4 mg every 3–4 weeks) to hormonal therapy or
chemotherapy reduced the number of persistent disseminated
tumor cells in the bone marrow compared with regular anticancer
therapy alone [14–17]. Such reductions in disseminated tumor
cells might lead to reduced tumor recurrences in these patients.
Two clinical trials that included patients with early breast cancer
who were either postmenopausal or premenopausal and received
ovarian suppression showed that adding twice-yearly zoledronic
acid (4 mg) to standard adjuvant endocrine therapy signiﬁcantly
improved disease-free survival (DFS) compared with endocrine
therapy alone [18,19]. Moreover, in patients with breast cancer
and bone marrow micrometastases, overall survival (OS)
improved with adjuvant clodronate compared with placebo
[20,21]. In a meta-analysis of randomized, controlled clinical
trials of BPs, adjuvant zoledronic acid reduced the risk of breast
cancer recurrence; however, overall, adjuvant BPs did not reduce
mortality, disease recurrence rates, or relapse rates in this
population [22]. Recent results from the Adjuvant Zoledronic acid
to redUce REcurrence (AZURE) trial, conducted in women with
early breast cancer, showed no signiﬁcant beneﬁt of adjuvant
zoledronic acid in the overall population, whereas signiﬁcant DFS
and OS beneﬁts were observed in a subset of women with
established postmenopausal status (i.e., 45 years postmeno-
pause at baseline) [23]. These results suggest that the anticancer
effects of BPs may be dependent on a low-estrogen environment.
In the current retrospective analysis, we assessed DFS and OS
in unselected patients with early breast cancer who received BPs
or no BPs at the St. Josefs Breast Centre in the St. Josefsklinik in
Offenburg, Germany, from 1997 to 2009. We report here the
results of the overall population and subgroups stratiﬁed by
hormone receptor status and nodal involvement.Endocrine therapy 778/778 100% 488/509 96%
Chemotherapy 581 62% 208 33% o0.001
Bisphosphonate therapy
Zoledronic acid 216 23% —
Ibandronate 238 25% —
Clodronate 87 9% —
Alendronate 152 16% —
Switch to zoledronic acid 98 11% —
Switch to other BP 93 10% —
Other BP or multiple BP switches 53 6% —
Patient subgroups included in Kaplan–Meier analyses
Nþ , ERþ Z10% 338 36% 171 27% o0.001
Hormone receptor negativea 154 16% 114 18% 0.36
BP, bisphosphonate; ER, estrogen receptor; HER2, human epidermal growth factor
receptor-2; Nþ , node positive; PgR, progesterone receptor; SD, standard deviation.
a Tumors were considered ER/PgR-positive if Z10% of cells were ER- and PgR-
positive, and HR-negative if o10% of cells were ER- and PgR-positive.2. Materials and methods
2.1. Data source
Clinical data were obtained between 1997 and 2009 from all
women who received treatment for early breast cancer at the St.
Josefs Breast Centre in the St. Josefsklinik in Offenburg, Germany.
2.2. Patient selection
This retrospective analysis included all patients with invasive
breast cancer and documented tumor-node-metastasis (TNM) stage
and hormone receptor status. Additionally, women included in theBP cohort of this study must have initiated BP therapy o1 year after
diagnosis of breast cancer and must have received BPs for Z3
months. These selection criteria were chosen to allow standard
therapy for breast cancer (i.e., surgery, chemotherapy, radiotherapy)
before initiation of BP therapy and to eliminate women with early
relapse or early noncompliance with BP therapy.
Patients included in the BP group received one of the follow-
ing: zoledronic acid 4 mg IV two to three times per year;
ibandronate 50 mg/day PO, 150 mg/month PO, or 4 mg to 6 mg
IV every 3 months; clodronate 1600 mg/day PO; or alendronate
70 mg/week PO. Some patients switched from one BP to another,
especially among those receiving oral agents.2.3. Statistical analyses
Disease-free survival was deﬁned as the time from breast
cancer diagnosis until ﬁrst disease recurrence or death. Disease-
free survival and OS were estimated using the Kaplan–Meier
method and were compared between the BP and no-BP groups
using the log-rank test. Hazard ratios (HRs) and 95% conﬁdence
intervals (CIs) for DFS and OS in BP- vs. no-BP-treated patients
were obtained via Cox regression models/multivariate analyses
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grade, estrogen receptor (ER) status, and progesterone receptor
(PgR) status. Data were stratiﬁed by hormone receptor and nodal
status. Tumors were considered to be hormone receptor-positive
if Z10% of cells were ER-positive (ERþ), and hormone receptor-
negative if o10% of cells were ERþ and PgR-positive (PgRþ).
Stratiﬁcation was based on nodal status. All results were based on
two-sided analyses and quantiﬁed with P values. A MaDoS
documentation system was used to access patient data on base-
line characteristics, clinical interventions, and outcomes. All
statistical calculations were performed using WinSTAT.
2.4. Calculations
From the clinical evidence presented thus far, BPs have a
theoretical role in adjuvant breast cancer therapy both to prevent
SREs during endocrine therapy and to provide anticancer beneﬁts. As
this knowledge becomes common among physicians, BP use during
adjuvant therapy in breast cancer may increase in clinical practices.Fig. 1. Frequency of bisphosphonate use d
Fig. 2. Kaplan–Meier estimates for disease-free survival in the overallExamining the management of breast cancer cases in a clinical
practice over the time course of the clinical data presentation would
reveal any effects of the clinical evidence on the real-world treatment
of breast cancer. Moreover, if adjuvant BP use increased, then clinical
beneﬁts from the addition of BPs to adjuvant therapy could be
assessed in the patient population treated in clinical practice. Data
from such an evaluation could provide realistic expectations of
treatment results on which physicians could base their treatment
decision. Therefore, we conducted this retrospective analysis of our
large and long-term patient database.3. Results
3.1. Study population
A total of 1646 women were eligible for inclusion in the
analysis, of whom 962 received BPs (BP group) and 684 did not
(no-BP group). At the date of database lock (November 1, 2012),uring the study period (1997–2009).
patient population treated with or without bisphosphonates (BPs).
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of adjuvant therapy in all patients, and thereafter until last
follow-up visit or documented death.
Demographic and baseline characteristics were generally
balanced between the two treatment groups, with the following
exceptions: fewer patients in the BP group compared with the no-BP
group had histologic grade 3 tumors (29% vs. 33%, respectively), and
more patients in the BP group were o75 years of age (87% vs. 74%,
respectively), node positive (43% vs. 34%, respectively), and had
received adjuvant chemotherapy (62% vs. 33%, respectively)
(Table 1). The majority of patients had tumors that were Z10%
ERþ (83% in the BP group and 81% in the no-BP groups) and Z70%
of women in each group had PgRþ tumors. In the BP group 100% of
patients received endocrine therapy, as did 96% of patients in the no-
BP group. The majority of patients in the BP group received (at any
time) ibandronate (25%), zoledronic acid (23%), or alendronate (16%).Fig. 3. Kaplan–Meier estimates of disease-free survival (A) and overall survival (B) in p
cancer (irrespective of nodal status) treated with or without bisphosphonates (BPs).3.2. Bisphosphonate use during the study period
The use of BPs increased during the 12-year study period, from
approximately 2% of patients in 1997 to 98% of patients in 2009
(Fig. 1). From 1997 to 2001, 34 of 380 patients (9%) received BPs
compared with 346 of 380 patients (91%) who did not, and from
2002 to 2009, 903 of 1187 patients (76%) received BPs compared
with 284 of 1187 (24%) who did not.
3.3. Efﬁcacy analysis
In the overall population at the end of follow-up, the DFS rate
was 83.0% in the BP group compared with 79.6% in the no-BP
group. Kaplan–Meier estimates of DFS demonstrated a statisti-
cally signiﬁcant improvement in patients who received BPs
compared with those who did not (P¼0.0017; Fig. 2).atients with hormone receptor-positive (Z10% estrogen receptor-positive) breast
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BP use were apparent irrespective of nodal status: 92.5% vs. 87.4%,
respectively (Fig. 2). In women with hormone receptor-positive
tumors and node-positive status (irrespective of the number of
lymph nodes affected), those treated with BPs (N¼796) had a
signiﬁcantly better 5-year DFS rate of 93.7% compared with 89.0%
for those in the no-BP group (N¼554; HR¼0.59; 95% CI, 0.41–
0.84; P¼0.0038; Fig. 3A). In this patient subset, BP treatment was
also associated with signiﬁcantly improved OS rates at 10 years
compared with no BP use (78.4% vs. 70.8%, respectively;
HR¼0.60; 95% CI, 0.43–0.84; Po0.0026; Fig. 3B), possibly inﬂu-
enced by the increased age in the no-BP group vs. the BP group
(age 470 years; mean age BP group, 77.175.7 vs. no-BP group,
78.675.5 years; standard deviation, 12.5 years) (data not shown).
The DFS beneﬁt of BP therapy was most profound among women
with hormone receptor-positive tumors who were node positive,
with 5-year DFS rates of 91.2% in the BP group (N¼346) and 76.6%Fig. 4. Kaplan–Meier estimates of disease-free survival (A) and overall survival (B) in
with or without bisphosphonates (BPs). Node-positive refers to N1-N3.in the no-BP group (N¼181; HR¼0.38; 95% CI, 0.25–0.59;
P¼0.000018; Fig. 4A). In this patient subset, BP treatment was
also associated with a statistically signiﬁcant improvement in OS
(HR¼0.56; 95% CI, 0.37–0.80; P¼0.006; Fig. 4B) potentially also
related to mean age differences between the groups. Interestingly,
in the subset of patients with hormone receptor-negative tumors
irrespective of nodal status, there was no statistically signiﬁcant
difference in DFS between the BP group (N¼159) and the no-BP
group (N¼121) at 5 and 10 years (86.5% vs. 81.6% and 78.3% vs.
80.4%, respectively, HR¼0.80; 95% CI, 0.45–1.46; P¼0.48; Fig. 5).
Among BP-treated patients with hormone receptor-positive
tumors (irrespective of nodal status), estrogen levels inﬂuenced
survival outcomes regardless of patient age. Disease-free survival
was signiﬁcantly longer in patients with estrogen levels o10 pg/
mL (N¼171) compared with patients with levels Z10 pg/mL
(N¼44) (HR¼0.17; 95% CI, 0.05–0.62; P¼0.007; Fig. 6A). The
between-group difference based on estrogen levels (o10 pg/mLpatients with node-positive and hormone receptor-positive breast cancer treated
Fig. 5. Kaplan–Meier estimates of disease-free survival in patients with hormone receptor-negative breast cancer (irrespective of nodal status) treated with or without
bisphosphonates (BPs).
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0.10–0.80; P¼0.018; Fig. 6B).
Additional analyses were performed to assess the potential
effects of imbalances in BP use during the study period (1997–
2001 and 2002–2009) and certain patient characteristics on the
outcomes of the study. Among patients with hormone receptor-
positive disease in the no-BP group for the periods 1997–2001
(N¼320) and 2002–2009 (N¼234), there were no statistically
signiﬁcant differences in DFS with regard to nodal status. Among
patients o75 years of age with hormone receptor-positive dis-
ease (irrespective of nodal status), 5-year DFS was signiﬁcantly
better in the BP group compared with the no-BP group (94.1% vs.
89.8%, respectively; HR¼0.62; 95% CI, 0.42–0.94; P¼0.023).
Similarly, among patients o75 years of age with node-positive
and receptor-positive disease, 5-year DFS was signiﬁcantly better
in the BP group (N¼295) compared with the no-BP group
(N¼124) (91.8% vs. 76.0%, respectively; HR¼0.39; 95% CI, 0.24–
0.63; P¼0.00013), but this beneﬁt did not extend to a statistically
signiﬁcant OS beneﬁt (HR¼0.68; 95% CI, 0.40–1.17; P¼0.17). In
patients with hormone receptor-positive, node-negative disease,
irrespective of age, no difference in DFS was observed among BP-
treated patients who received chemotherapy (N¼138) and those
who did not receive chemotherapy (N¼312) (96.0% vs. 96.1%,
respectively). This comparison was not possible for the no-BP
group given the small number of patients (N¼18) in this sub-
group who received chemotherapy.4. Discussion
This retrospective analysis examined data from patients with
early breast cancer treated over a 12-year period (1997–2009) in
a real-world setting. The proportion of patients receiving adjuvant
BP therapy dramatically increased during the study period, from
o2% in 1997 to nearly 100% in 2009 (Fig. 1), presumably
because of proactive management of bone health and accum-
ulating evidence of the potential anticancer beneﬁts of BPs
[18,19,24–26]. For example, the earliest clinical evidence of suchbeneﬁts, demonstrated with clodronate, contributed to a modest
increase in BP use of approximately 10% in 1998 and 1999. In
2001 and 2002, BP use more than doubled with the introduction
of zoledronic acid. Moreover, initial reports from the Austrian
Breast and Colorectal Cancer Study Group-12 (ABCSG-12) and
Zometa–Femara Adjuvant Synergy Trial (ZO-FAST) trials of the
anticancer potential of zoledronic acid increased BP use to 90% or
more in 2008 and 2009. Our analysis revealed that BP therapy
initiated within 1 year of breast cancer diagnosis and continued
for at least 3 months was associated with signiﬁcantly prolonged
DFS compared with no BP therapy in women receiving adjuvant
therapy for early breast cancer. The beneﬁts of adjuvant BP
therapy appear more pronounced in women with hormone
receptor-positive vs. hormone receptor-negative tumors and
increased with the extent of lymph node involvement; indeed,
even OS beneﬁts could be observed in this patient subgroup.
These ﬁndings are consistent with those of previous clinical trials
evaluating anticancer beneﬁts with BPs in the adjuvant breast
cancer setting [18,19,27,28].
To date, the most promising data on the potential anticancer
beneﬁts of BPs have been reported with zoledronic acid. Three
clinical trials have directly assessed the effects of adjuvant
zoledronic acid on disease recurrence and survival in women
receiving various adjuvant therapies for breast cancer. In the
ABCSG-12 trial, 1803 premenopausal women with hormone
receptor-positive early breast cancer received ovarian suppres-
sion with the gonadotropin-releasing hormone analogue goser-
elin and were treated with tamoxifen or anastrozole with or
without zoledronic acid for 3 years [19]. At a median follow-up of
48 months, the combination of zoledronic acid plus endocrine
therapy signiﬁcantly reduced the relative risk of disease progres-
sion by 36% (HR¼0.64; P¼0.01) and the risk of recurrence by 35%
(HR¼0.65; P¼0.01) compared with endocrine therapy alone.
These zoledronic acid beneﬁts were maintained at the 84-month
follow-up, more than 5 years after treatment completion, for both
DFS (HR¼0.72; P¼0.014) and OS (HR¼0.63; P¼0.049), and were
greatest among women 440 years of age at study entry com-
pared with women r40 years of age (DFS: HR¼0.66, P¼0.013;
Fig. 6. Kaplan–Meier estimates of disease-free survival (A) and overall survival (B) in bisphosphonate (BP)-treated patients with hormone receptor-positive breast cancer
(irrespective of nodal status), by estrogen levels.
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effects of immediate versus delayed zoledronic acid on bone
mineral density, disease recurrence, and survival in 1065 post-
menopausal women with hormone receptor-positive early breast
cancer who received adjuvant therapy with letrozole [18]. Com-
pared with delayed zoledronic acid treatment, immediate zole-
dronic acid was associated with a signiﬁcant 41% reduction in the
risk of DFS events (HR¼0.59; P¼0.0314) at 36 months [18], and
continued to reduce the risk at 60 months (HR¼0.66; P¼0.0375)
[30]. Treatment with immediate zoledronic acid reduced both
skeletal and nonskeletal DFS events compared with delayed
zoledronic acid [30]. In contrast, in the AZURE trial (N¼3360) in
women with breast cancer who received standard adjuvant
systemic therapy (including endocrine therapy), zoledronic acid
therapy did not show a survival beneﬁt at 59 months in the
overall population [23]. However, prespeciﬁed subgroup analyses
in women who had been postmenopausal for more than 5 years atbaseline (N¼1041) showed that adding zoledronic acid signiﬁ-
cantly improved invasive DFS (HR¼0.75; P¼0.02) and OS
(HR¼0.74; P¼0.04) [23,28]. In contrast to our retrospective
analysis, the beneﬁcial effects of zoledronic acid on disease
recurrence and survival outcomes in the postmenopausal subset
in AZURE were independent of hormone-receptor status and the
extent of lymph node involvement (all study participants in
AZURE were node positive at study entry) [23]. Data from these
trials suggest that estrogen effects on the bone microenvironment
may play a role in determining the characteristics of patients
most likely to beneﬁt from adjuvant zoledronic acid therapy.
Therefore, patients with hormone receptor-negative disease in
our analysis likely did not beneﬁt from BP therapy because they
did not receive endocrine therapy and consequently would have
had higher estrogen levels. Ongoing trials evaluating bone-
targeted therapies in the adjuvant setting for anticancer beneﬁts
include denosumab in women with high-risk early breast cancer
P. Hadji et al. / Journal of Bone Oncology 2 (2013) 2–10 9receiving neoadjuvant or adjuvant therapy (D-CARE) [31] and
zoledronic acid, clodronate, and ibandronate in women with
stage 1, 2, or 3 breast cancer receiving adjuvant therapy after
surgery [32].
Results of the current retrospective analysis must be inter-
preted with several limitations in mind. First, although a retro-
spective study may provide a window into real-world clinical
outcomes, it is not powered to detect differences to the same
degree as a prospective, controlled trial. Moreover, the current
patient population was heterogeneous with respect to BP and
anticancer therapy use and certain baseline characteristics, and
statistical adjustment for confounding variables was not included
in the analysis. Finally, adverse events were not captured and
analyzed, which prevented assessment of the beneﬁt:risk proﬁle
associated with adjuvant BPs in clinical practice.
In conclusion, this large, single-center, retrospective study
demonstrated signiﬁcant DFS beneﬁt in patients with early breast
cancer who received adjuvant BPs compared with no BPs. The DFS
beneﬁt was most notable in BP-treated patients with node-
positive and hormone receptor-positive breast cancer; however,
the inﬂuence of estrogen levels on outcomes was clearly evident
and it remains possible that even patients with hormone
receptor-negative disease may beneﬁt from BP therapy if their
estrogen levels are low. These analyses support the anticancer
activity of adjuvant BPs demonstrated in several large phase
3 trials involving more than 6000 patients with early breast
cancer. The results of these trials and our retrospective analysis,
although promising, indicate a need to further reﬁne our under-
standing of the effects of BPs on disease outcomes and the patient
populations that may beneﬁt most from BP therapy.Approval statement
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